BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors. 2020

Yuhong Dong, and Hao Hu, and Yuwei Sun, and Mingze Qin, and Ping Gong, and Yunlei Hou, and Yanfang Zhao
Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University), Ministry of Education, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.

In this work three novel series of c-Met/HDAC bifunctional inhibitors were designed and synthesized by merging pharmacophores of c-Met and HDAC inhibitors. The most potent compound 11j inhibited c-Met kinase and HDAC1 with IC50 values of 21.44 and 45.22 nM, respectively. In addition, 11j showed efficient antiproliferative activities against both MCF-7 and A549 cells with greater potency than the reference drug SAHA and Cabozantinib. This work may lay the foundation for developing novel dual c-Met/HDAC inhibitors as potential anticancer therapeutics.

UI MeSH Term Description Entries
D010671 Phenylurea Compounds Compounds that include the amino-N-phenylamide structure. Phenylcarbamides,Phenylurea Derivatives,Compounds, Phenylurea,Derivatives, Phenylurea
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011804 Quinolines
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Yuhong Dong, and Hao Hu, and Yuwei Sun, and Mingze Qin, and Ping Gong, and Yunlei Hou, and Yanfang Zhao
Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors.
June 2019, Molecules (Basel, Switzerland),
Yuhong Dong, and Hao Hu, and Yuwei Sun, and Mingze Qin, and Ping Gong, and Yunlei Hou, and Yanfang Zhao
Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
November 2022, Bioorganic & medicinal chemistry,
Yuhong Dong, and Hao Hu, and Yuwei Sun, and Mingze Qin, and Ping Gong, and Yunlei Hou, and Yanfang Zhao
Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives.
August 2017, ACS medicinal chemistry letters,
Yuhong Dong, and Hao Hu, and Yuwei Sun, and Mingze Qin, and Ping Gong, and Yunlei Hou, and Yanfang Zhao
Design, synthesis, and biological evaluation of potent c-Met inhibitors.
September 2008, Journal of medicinal chemistry,
Yuhong Dong, and Hao Hu, and Yuwei Sun, and Mingze Qin, and Ping Gong, and Yunlei Hou, and Yanfang Zhao
Design, synthesis, and biological evaluation of novel HDAC/CD13 dual inhibitors for the treatment of cancer.
November 2023, European journal of medicinal chemistry,
Yuhong Dong, and Hao Hu, and Yuwei Sun, and Mingze Qin, and Ping Gong, and Yunlei Hou, and Yanfang Zhao
Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors.
April 2014, ACS medicinal chemistry letters,
Yuhong Dong, and Hao Hu, and Yuwei Sun, and Mingze Qin, and Ping Gong, and Yunlei Hou, and Yanfang Zhao
Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
July 2017, Bioorganic & medicinal chemistry,
Yuhong Dong, and Hao Hu, and Yuwei Sun, and Mingze Qin, and Ping Gong, and Yunlei Hou, and Yanfang Zhao
Design, Synthesis, and Biological Evaluation of [1,2,4]triazolo[4,3-a] Pyrazine Derivatives as Novel Dual c-Met/VEGFR-2 Inhibitors.
January 2022, Frontiers in chemistry,
Yuhong Dong, and Hao Hu, and Yuwei Sun, and Mingze Qin, and Ping Gong, and Yunlei Hou, and Yanfang Zhao
Novel 3-phenylquinazolin-2,4(1H,3H)-diones as dual VEGFR-2/c-Met-TK inhibitors: design, synthesis, and biological evaluation.
October 2023, Scientific reports,
Yuhong Dong, and Hao Hu, and Yuwei Sun, and Mingze Qin, and Ping Gong, and Yunlei Hou, and Yanfang Zhao
Design, synthesis, and biological evaluation of thieno[2,3-d]pyrimidine derivatives as novel dual c-Met and VEGFR-2 kinase inhibitors.
December 2017, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!